LEXICON PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
LEXICON PHARMACEUTICALS, INC. (LXRX) had Available-for-sale Securities, Amortized Cost Basis of $18.42 million as of 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2023-03-03
- 2022-12-31: Available-for-sale Securities, Amortized Cost Basis $18.42M.
- 2021-12-31: Available-for-sale Securities, Amortized Cost Basis $26.02M; Available-for-sale Securities, Amortized Cost Basis as first filed $15.13M.
- 2020-12-31: Available-for-sale Securities, Amortized Cost Basis $26.02M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2022-12-31 | $18.42M 10-K · filed 2023-03-03 | |
| 2021-12-31 | $26.02M 10-K · filed 2023-03-03 | $15.13M 10-K · filed 2022-03-10 |
| 2020-12-31 | $26.02M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |